Showing results (401-410 of 463) with videos related to
Sort By:
Pageof 47
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2010
Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205Philip A Philip, Jacqueline Benedetti, Christopher L Corless, et al.The American Journal of Gastroenterology|November 11, 2018
High-Grade Dysplasia in Resected Main-Duct Intraductal Papillary Mucinous Neoplasm (MD-IPMN) is Associated with an Increased Risk of Subsequent Pancreatic CancerShounak Majumder, Nissy A Philip, Sajan Jiv Singh Nagpal, et al.Journal of Hepatocellular Carcinoma|June 4, 2024
A Post-International Gastrointestinal Cancers' Conference (IGICC) Position StatementsSuayib Yalcin, Sahin Lacin, Ahmed Omar Kaseb, et al.Molecular Cancer Therapeutics|October 10, 2020
Molecular Characterization of Appendiceal Goblet Cell CarcinoidHiroyuki Arai, Yasmine Baca, Francesca Battaglin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2016
Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice GuidelineDavendra P S Sohal, Pamela B Mangu, Alok A Khorana, et al.Biomaterials|December 4, 2014
The uptake of soluble and nanoparticulate imaging isotope in model liver tumours after intra-venous and intra-arterial administrationRoss W Stephens, Karen J Knox, Lee A Philip, et al.Molecular Cancer Therapeutics|November 2, 2021
Association of Homologous Recombination-DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal CancersMichael Cerniglia, Joanne Xiu, Axel Grothey, et al.Cancer Research Communications|May 16, 2022
Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C-Mutant CancersHusain Yar Khan, Misako Nagasaka, Yiwei Li, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2021
Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513E Gabriela Chiorean, Katherine A Guthrie, Philip A Philip, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2024
Differential Responses to Immune Checkpoint Inhibitors are Governed by Diverse Mismatch Repair Gene AlterationsMoh'd M Khushman, Michael D Toboni, Joanne Xiu, et al.Pageof 47